Naozumi Harada

2.4k citations

31 papers · 1.9k indexed · 1 hit paper · h-index 16

Cancer Research top 5%
Immunology top 5%
- Immunotherapy and Immune Responses 19
- Immune Cell Function and Interaction 5
- Immune cells in cancer 4
Neurology top 5%
Molecular Biology top 5%
- RNA Interference and Gene Delivery 7
- Extracellular vesicles in disease 3
Oncology top 10%
- Cancer Immunotherapy and Biomarkers 5
- CAR-T cell therapy research 4
Pathology and Forensic Medicine
- Multiple Sclerosis Research Studies 3

Co-authors: Hiroshi Shiku Kazunari Akiyoshi Shin‐ichi Sawada Sada‐atsu Mukai Yuko Sato Kaori Umezaki Yoshihiro Sasaki Takaharu Yamamoto
Cited by: Cancer Research Immunology Neurology
Journals: Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (1 paper)Nature Communications (1 paper)
Partner nations: Japan United States Switzerland

In The Last Decade

Naozumi Harada

29 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Naozumi Harada

Since Specialization

Citations

This map shows the geographic impact of Naozumi Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naozumi Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naozumi Harada more than expected).

Fields of papers citing papers by Naozumi Harada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naozumi Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naozumi Harada. The network helps show where Naozumi Harada may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Naozumi Harada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Naozumi Harada Line = papers co-authored together Naozumi Harada links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Antitumor immune response elicited by M2 TAM-specific DDS via C-type lectin CD209b using cholesteryl pullulan nanogel as a protein drug carrier Biomaterials Science ·Takaaki Nakatsukasa,Daisuke Muraoka,Situo Deng,Kiyoshi Yasui,Shin‐ichi Sawada,Asako Shimoda,Hirokazu Matsushita,Keitaro Matsumoto,Takeshi Nagayasu,Naozumi Harada,Kazunari Akiyoshi,Hiroaki Ikeda	2025	0
2	Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice npj Vaccines ·Daisuke Muraoka,Meng Ling Moi,Osamu Muto,Takaaki Nakatsukasa,Situo Deng,Chieko Takashima,Rui Yamaguchi,Shin‐ichi Sawada,Haruka Hayakawa,Thi Thanh Ngan Nguyen,Yasunari Haseda,Takatoshi Soga,Hirokazu Matsushita,Hiroaki Ikeda,Kazunari Akiyoshi,Naozumi Harada	2024	1
3	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance Journal of Controlled Release ·Daisuke Muraoka,Naozumi Harada,Hiroshi Shiku,Kazunari Akiyoshi	2022	33
4	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors Cancer Immunology Immunotherapy ·Mikiya Ishihara,Yasutaka Tono,Yoshihiro Miyahara,Daisuke Muraoka,Naozumi Harada,Shinichi Kageyama,Takeshi Sasaki,Yasuhide Hori,Norihito Soga,Katsunori Uchida,Taizo Shiraishi,Eiichi Sato,Hideki Kanda,Toshiro Mizuno,Gill Webster,Hiroaki Ikeda,Naoyuki Katayama,Yoshiki Sugimura,Hiroshi Shiku	2020	21
5	MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours BMC Cancer ·Mikiya Ishihara,Shinichi Kageyama,Yoshihiro Miyahara,Takeshi Ishikawa,Shugo Ueda,Norihito Soga,Hiroaki Naota,Katsumi Mukai,Naozumi Harada,Hiroaki Ikeda,Hiroshi Shiku	2020	33
6	Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein Vaccine ·Daisuke Muraoka,Deng Situo,Shin‐ichi Sawada,Kazunari Akiyoshi,Naozumi Harada,Hiroaki Ikeda	2020	7
7	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance Journal of Clinical Investigation ·Daisuke Muraoka,Naohiro Seo,Tae Hayashi,Yoshiro Tahara,Keisuke Fujii,Isao Tawara,Yoshihiro Miyahara,Kana Okamori,Hideo Yagita∥,Seiya Imoto,Rui Yamaguchi,Mitsuhiro Komura,Satoru Miyano,Masahiro Goto,Shin‐ichi Sawada,Akira Asai,Hiroaki Ikeda,Kazunari Akiyoshi,Naozumi Harada,Hiroshi Shiku	2019	117
8	Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells Nature Communications ·Naohiro Seo,Yoshitaka Shirakura,Yoshiro Tahara,Fumiyasu Momose,Naozumi Harada,Hiroaki Ikeda,Kazunari Akiyoshi,Hiroshi Shiku	2018	178
9	Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation Oncotarget ·Daisuke Muraoka,Naohiro Seo,Tae Hayashi,Chisaki Hyuga-Amaike,Kana Okamori,Isao Tawara,Naozumi Harada,Hiroshi Shiku	2017	6
10	Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis Multiple Sclerosis and Related Disorders ·Takahiko Saida,Jun‐ichi Kira,Yasuhiro Ueno,Naozumi Harada,Toshiyuki Hirakata	2016	8
11	Engineering hybrid exosomes by membrane fusion with liposomesbreakdown → Scientific Reports ·Yuko Sato,Kaori Umezaki,Shin‐ichi Sawada,Sada‐atsu Mukai,Yoshihiro Sasaki,Naozumi Harada,Hiroshi Shiku,Kazunari Akiyoshi	2016	605
12	Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types PLoS ONE ·Fumiyasu Momose,Naohiro Seo,Yasushi Akahori,Shin‐ichi Sawada,Naozumi Harada,Toru Ogura,Kazunari Akiyoshi,Hiroshi Shiku	2016	15
13	Outcomes of pregnancy during interferon beta‐1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study Clinical and Experimental Neuroimmunology ·Yuko Shimizu,Haruki Makioka,Naozumi Harada,Shoko Nakabayashi,Takahiko Saida,Jun‐ichi Kira	2015	3
14	Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells Vaccine ·Daisuke Muraoka,Hiroyoshi Nishikawa,Takuro Noguchi,Linan Wang,Naozumi Harada,Eiichi Sato,Immanuel F. Luescher,Eiichi Nakayama,Takuma Kato,Hiroshi Shiku	2013	6
15	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients Journal of Translational Medicine ·Shinichi Kageyama,Hisashi Wada,Kei Muro,Yasumasa Niwa,Shugo Ueda,Hiroshi Miyata,Shuji Takiguchi,Sahoko Sugino,Yoshihiro Miyahara,Hiroaki Ikeda,Naoko Imai,Eiichi Sato,Tomomi Yamada,Masaharu Osako,Mami Ohnishi,Naozumi Harada,T Hishida,Yuichiro� Doki,Hiroshi Shiku	2013	95
16	Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling Cancer Research ·Hiroyoshi Nishikawa,Takuma Kato,Michiko Hirayama,Yuki Orito,Eiichi Sato,Naozumi Harada,Sacha Gnjatic,Lloyd J. Old,Hiroshi Shiku	2008	66
17	Solid-Phase synthesis of a library constructed of aromatic phosphate, long alkyl chains and tryptophane components, and identification of potent dipeptide telomerase inhibitors Bioorganic & Medicinal Chemistry Letters ·Shinya Sasaki,Takeru Ehara,Md. Rowshon Alam,Yasuhiro Fujino,Naozumi Harada,Junko Kimura,Hideo Nakamura,Minoru Maëda	2001	2
18	Development of novel telomerase inhibitors based on a Bisindole unit Bioorganic & Medicinal Chemistry Letters ·Shinya Sasaki,Takeru Ehara,Ikuhiro Sakata,Yasuhiro Fujino,Naozumi Harada,Junko Kimura,Hideo Nakamura,Minoru Maëda	2001	15
19	In VivoInteraction of AF-6 with Activated Ras and ZO-1 Biochemical and Biophysical Research Communications ·Takaharu Yamamoto,Naozumi Harada,Yoji Kawano,Shinichiro Taya,Kozo Kaibuchi	1999	52
20	Identification of AF-6 and Canoe as Putative Targets for Ras Journal of Biological Chemistry ·Masamitsu Kuriyama,Naozumi Harada,Shinya Kuroda,Takaharu Yamamoto,Masato Nakafuku,Akihiro Iwamatsu,Daisuke Yamamoto,R Prasad,Carlo M. Croce,Eli Canaani,Kozo Kaibuchi	1996	179

About Naozumi Harada

Naozumi Harada is a scholar working on Immunology, Oncology and Molecular Biology, having authored 31 papers that have together received 1.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (19 papers), RNA Interference and Gene Delivery (7 papers), Immune Cell Function and Interaction (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), CAR-T cell therapy research (4 papers), Immune cells in cancer (4 papers), Extracellular vesicles in disease (3 papers) and Multiple Sclerosis Research Studies (3 papers). The work is most often cited by research in Cancer Research (456 citations), Immunology (568 citations) and Neurology (182 citations). Naozumi Harada has collaborated with scholars based in Japan, United States and Switzerland. Frequent co-authors include Hiroshi Shiku, Kazunari Akiyoshi, Shin‐ichi Sawada, Sada‐atsu Mukai, Yuko Sato, Kaori Umezaki, Yoshihiro Sasaki, Takaharu Yamamoto, Kozo Kaibuchi and Eli Canaani. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact